Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||15 Mar 2019||Lorem|
|Sangamo’s Phase I SB-913 study in MPS II unlikely to see neurological disease changes but somatic manifestations have better chance, experts say||17 Oct 2018||Mina Moawad|
|Sangamo’s gene therapy clinical development less appealing if hemophilia A trial repeats preclinical immunosuppression strategy, experts say||16 Mar 2018||Alaric DeArment|
|Sangamo’s next trial of MPS-1 gene therapy raises design challenges around patient variability, CNS measures and control arm -- experts||29 Jan 2018||Fiona Barry,;Hamish McDougall|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer